NervGen Pharma Corp. (NGEN.V) TSXV

2.80

-0.12(-4.11%)

Updated at August 18 03:59PM

Currency In CAD

NervGen Pharma Corp.

Address

2955 Virtual Way

Vancouver, BC V5M 4X6

Canada

Phone

778 731 1711

Sector

Healthcare

Industry

Biotechnology

Employees

11

First IPO Date

March 15, 2019

Key Executives

NameTitlePayYear Born
Mr. Michael P. KellyChief Executive Officer, President & Director1.11M1965
Mr. William J. Adams C.A., CPA, CA, CPAChief Financial Officer & Corporate Secretary483,6831962
Dr. Daniel D. Mikol M.D., Ph.D.Chief Medical Officer767,900N/A
Mr. Brian McAlisterCo-Founder & Advisor0N/A
Dr. Charles V. Olson D.Sc.Senior Vice President of Technical Operations01957
Mr. Kevin M. RooneySenior Vice President of Corporate Development & Strategy01966
Mr. William Joseph Radvak BAScCo-Founder & Advisor01963
Dr. Harold Martin Punnett D.M.D.Co-Founder & Independent Director0N/A
Ms. Elizabeth Eberhardt B.Sc.Senior Vice President of Program Management0N/A

Description

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.